Xalkori: A Revolution in Lung Cancer Treatment
Links shared publicly online about this topic.
- 34total visits
Xalkori: A Revolution in Lung Cancer Treatment
View full resource at onclive.com
Tags: Genetic, Cancer, Lung Cancer, Lung, Disease and Condition, Smoking Cessation, disease
Most Recently Shared on August 30, 2011 at 9:14 pm By:
Xalkori: A Revolution in Lung Cancer Treatment http://t.co/XEembRx #lungcancer
New Drug Approved For Treatment Of Non Small Cell Lung Cancer In Specific Patient Population
medicalnewstoday.com — “Lung Cancer Alliance (LCA) applauds the Food and Drug Administration (FDA) approval of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) who are ALK positive. The drug was approved bas” View full resource at medicalnewstoday.com
Most Recently Shared on September 6, 2011 at 8:05 am By:
New Drug Approved For Treatment Of Non Small Cell Lung Cancer In Specific Patient Population http://mnt.to/3Zrw #lungcancer
Lung Cancer Pill Holds Promise For Those Who Pass Test : Shots - Health Blog : NPR
npr.org — “Only people with lung cancer that tests positive for a particular genetic variation are candidates for treatment with Pfizer's twice-a-day cancer pill called Xalkori. Most of those who qualified in clinical tests saw dramatic shrinkage of their tumors.” View full resource at npr.org
Most Recently Shared on September 1, 2011 at 12:09 am By:
Lung Cancer Pill Holds Promise For Those Who Pass Test : NPR http://t.co/tHS0iMV
Lung Cancer Pill Holds Promise For Those Who Pass Test : Shots - Health Blog : NPR
npr.org — “Only people with lung cancer that tests positive for a particular genetic variation are candidates for treatment with Pfizer's twice-a-day cancer pill called Xalkori. Most of those who qualified in clinical tests saw dramatic shrinkage of their tumors.” View full resource at npr.org
Most Recently Shared on August 30, 2011 at 3:28 pm By:
krupali tejura, m.d. Doctor, Oncologist, Radiation Oncologist, and Physician
Lung #Cancer Pill Holds Promise For Those Who Pass Test-More at http://n.pr/qPVje7
Lung Cancer Treatment Xalkori Approved By FDA | ThirdAge
thirdage.com — “The lung cancer drug Xalkori (crizotinib) has been approved by the U.S. Food and Drug Administration for treating advanced non-small cell lung cancer (NSCLC) with a particular genetic abnormality.” View full resource at thirdage.com
Most Recently Shared on August 30, 2011 at 12:28 am By:
Lung Cancer Treatment Xalkori Approved By FDA: The lung cancer drug Xalkori (crizotinib) has been approved by th... http://t.co/ZrsHET0
Ahead of the Bell: Analyst sees Pfizer drug growth - Yahoo! News
news.yahoo.com — “Read 'Ahead of the Bell: Analyst sees Pfizer drug growth' on Yahoo! News. Pfizer Inc.'s newly approved lung cancer treatment Xalkori could bring in as much as $1 billion in sales by 2015, but its acceptance depends heavily on a new Abbott Laboratories gene test, according to a Citi analyst.” View full resource at news.yahoo.com
Most Recently Shared on August 29, 2011 at 6:35 pm By:
Ahead of the Bell: Analyst sees Pfizer drug growth: Pfizer Inc.'s newly approved lung cancer treatment Xalkori ... http://t.co/FOvejC2
Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC
news-medical.net — “Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.” View full resource at news-medical.net
Most Recently Shared on August 29, 2011 at 6:26 am By:
News-Medical.Net Oncology and Health News
Oncology News: Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC: Pfizer Inc. announ... http://t.co/oDwr8Us
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene
medicalnewstoday.com — “The US FDA has approved Xalkori (crizotinib) for the treatment of late-stage NSCLC (non-small cell lung cancer) in patients who have the abnormal ALK (anaplastic lymphoma kinase) gene. Patients un” View full resource at medicalnewstoday.com
Most Recently Shared on August 27, 2011 at 5:16 am By:
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene: The US FDA has approved Xalkori ... http://t.co/UQkBTuN
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene - QualityPoint Technologies
qualitypointtech.net — “The US FDA has approved Xalkori (crizotinib) for the treatment of late-stage NSCLC (non-small cell lung cancer) in patients who have the abnormal ALK (anaplastic lymphoma kinase) gene. Patients undergo a genetic test, known as the Vysis ALK Break Apart FISH Probe Kit which detects the abnormal gene. The FDA has also approved this test. The abnormal ALK gene causes cancer to develop and grow. Approximately 1% to 7% of patients with non-small cell lung cancer have this genetic abnormality. They ar” View full resource at qualitypointtech.net
Most Recently Shared on August 27, 2011 at 4:45 am By:
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene: The US FDA has approved Xalkori (c... http://t.co/IX8ESfO
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene - QualityPoint Technologies
qualitypointtech.net — “The US FDA has approved Xalkori (crizotinib) for the treatment of late-stage NSCLC (non-small cell lung cancer) in patients who have the abnormal ALK (anaplastic lymphoma kinase) gene. Patients undergo a genetic test, known as the Vysis ALK Break Apart FISH Probe Kit which detects the abnormal gene. The FDA has also approved this test. The abnormal ALK gene causes cancer to develop and grow. Approximately 1% to 7% of patients with non-small cell lung cancer have this genetic abnormality. They ar” View full resource at qualitypointtech.net
Most Recently Shared on August 27, 2011 at 1:45 am By:
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene: The US FDA has approved Xalkori (c... http://t.co/M9EhGbr
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene
medicalnewstoday.com — “The US FDA has approved Xalkori (crizotinib) for the treatment of late-stage NSCLC (non-small cell lung cancer) in patients who have the abnormal ALK (anaplastic lymphoma kinase) gene. Patients un” View full resource at medicalnewstoday.com
Most Recently Shared on August 27, 2011 at 12:05 am By:
Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene http://mnt.to/3Zf5 #healthnews
Advertisement
